Connacht Asset Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Connacht Asset Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	$217K	Sell	7,295 -5,111	-41%	-$105K	1.29%	43
2023 Q2	$224K	Sell	12,406 -985	-7%	-$19.6K	0.31%	89
2023 Q1	$215K	Buy	13,391 +1,054	+9%	+$19.5K	0.09%	130
2022 Q4	$226K	Sell	12,337 -2,786	-18%	-$49.1K	0.1%	106
2022 Q3	$297K	Buy	15,123 +3,842	+34%	+$78.3K	0.21%	98
2022 Q2	$210K	Buy	+11,281	New	+$225K	0.09%	142

Other funds holding CRNX

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Connacht Asset Management's CRNX Position: Q3 2023 in Review

Connacht Asset Management reduced its Crinetics Pharmaceuticals (CRNX) stake by 41% in Q3 2023, selling an estimated $105K and leaving 7,295 shares worth $217K. The position accounts for 1.29% of the portfolio, ranked #43.

Connacht Asset Management first reported a position in CRNX in Q2 2022 and has held it in 6 quarters since. The position peaked at $297K in Q3 2022. 171 funds tracked by Wall St. Rank hold CRNX as of Q3 2023.

Connacht Asset Management held 7,295 shares of Crinetics Pharmaceuticals worth $217K as of Q3 2023.
Connacht Asset Management sold 5,111 Crinetics Pharmaceuticals shares in Q3 2023, an estimated $105K.
Crinetics Pharmaceuticals made up 1.29% of Connacht Asset Management's portfolio in Q3 2023, its #43 holding.
Connacht Asset Management first reported a position in Crinetics Pharmaceuticals in Q2 2022 and has held it in 6 quarters since.
Connacht Asset Management's Crinetics Pharmaceuticals position peaked at $297K in Q3 2022.
171 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q3 2023.

Based on Connacht Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.